May Clearing Nasal Viruses Improve Allergic Rhinitis? - Scorecard - MDSpire

May Clearing Nasal Viruses Improve Allergic Rhinitis?

A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.

  • By

  • Andrea Surnit

  • July 7, 2026

  • 4 min

Share

Clinical Scorecard: May Clearing Nasal Viruses Improve Allergic Rhinitis?

At a Glance

CategoryDetail
ConditionAllergic Rhinitis
Key MechanismsActivation of type I interferon signaling and downstream inflammatory pathways by nasal commensal viruses.
Target PopulationPatients with allergic rhinitis.
Care SettingPhase 2 randomized clinical trial.

Key Highlights

  • Ribavirin nasal spray reduced Total Nasal Symptom Score after 4 weeks compared to placebo.
  • Improvements noted in Visual Analog Scale and Rhinitis Control Assessment Test scores.
  • Ribavirin treatment decreased nasal commensal virus abundance.
  • No serious adverse events reported during the study.
  • Exploratory follow-up suggested lower symptom scores and reduced medication use in ribavirin group.

Guideline-Based Recommendations

Diagnosis

  • Assess Total Nasal Symptom Score and other relevant scales.

Management

  • Consider ribavirin nasal spray as a potential treatment for allergic rhinitis.

Monitoring & Follow-up

  • Monitor for adverse events and symptom improvement during treatment.

Risks

  • Further validation needed in larger, multicenter phase 3 trials.

Patient & Prescribing Data

Patients with allergic rhinitis experiencing symptoms.

Ribavirin may improve symptoms in patients with higher baseline viral abundance.

Clinical Best Practices

  • Conduct thorough assessments of nasal symptom severity.
  • Evaluate the potential role of nasal commensal viruses in allergic rhinitis.

Related Resources & Content

Original Source(s)

May Clearing Nasal Viruses Improve Allergic Rhinitis?

  • by Andrea Surnit

  • July 7, 2026

Related Content

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.